$NSRX

Nasus Pharma (NYSE: NSRX) has enrolled and dosed the first patient in a Phase 1 trial for NS003, its intranasal ondansetron formulation. Pre-clinical studies showed NS003's PK profile was comparable to IV ondansetron, with a favorable safety profile. The company aims to announce topline PK data before year-end and initiate a pivotal NS002 study for anaphylaxis in Q4. Ondansetron is widely used for chemotherapy-induced nausea and vomiting, with peak sales exceeding $1.5 billion in 2023.

Tyra Biosciences (TYRA) raised $400M via stock offering for clinical development, shares up 15%. Nasus Pharma (NSRX) cleared FDA IND for NS002, shares up 10%. Bionano Genomics (BNGO) peer-reviewed studies showed OGM's effectiveness, shares up 9%. Tenaya Therapeutics (TNYA) received FDA RMAT designation for TN-401, shares up 9%.

Nasus Pharma Ltd. (NSRX) announced CFO Eyal Rubin's departure to pursue a new opportunity. Rubin will stay until September 18, 2026, to ensure a smooth transition. Oren Elmaliach, Director of Finance, has been appointed Interim CFO. Elmaliach has extensive financial experience and knowledge of the company's operations.

Nasus Pharma Ltd (NSRX) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update Appointed Pharma Industry Veteran Brendan O’Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, August

Teleman Dan Benjamin (Chief Executive Officer) purchased 6,550 shares of Nasus Pharma Ltd (NSRX) at $3.10 on 2026-06-17.

Nasus Pharma, a clinical-stage pharmaceutical company, announced its participation in two upcoming investor conferences in May 2026. CFO Eyal Rubin will attend the "Market Movers Investor Summit" and the "D. Boral Capital Global Conference" in New York, engaging in one-on-one meetings with interested investors. The company focuses on developing innovative intranasal products, including NS002, an intranasal epinephrine product for anaphylaxis.

Funicular Funds, Cable Car Capital, and Jacob Ma-Weaver have collectively reported a 5.2% beneficial ownership stake in Nasus Pharma Ltd (NSRX), totaling 612,913 Ordinary Shares each. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The ownership calculation is based on 11,710,808 shares outstanding as of March 27, 2026.

TEL AVIV, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Nasus Pharma Ltd. ( NYSE:NSRX ) ( "Nasus Pharma", "Nasus" or the "Company" ) , a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment ...

The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can achieve faster and higher absorption of epinephrine compared to an autoinjector

TEL AVIV, Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Nasus Pharma Ltd. ( NYSE:NSRX ) ( "Nasus Pharma" or the "Company" ) , a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that it recently ...